Business
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
RAHWAY, N.J., October 21, 2025--Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE in U.S. Adults
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/83a263cce1230753ba97048fa915a1a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KwvoyBKbclWo7Y1kQfoACw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/83a263cce1230753ba97048fa915a1a5","width":480,"height":217}},"lazy":false},{"type":"text","content":"Findings presented at IDWeek 2025 underscore the importance of considering serotypes that disproportionately impact adults in the U.S. and show greater resistance to commonly prescribed antibiotics","length":197,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., October 21, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a systematic literature review of studies on the epidemiology and antimicrobial resistance (AMR) of pneumococcal serotypes covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. adults. The evaluation examined 15 studies published between 2015 and 2025 to assess the serotype-specific burden of pneumococcal disease (PD) associated with serotypes covered by CAPVAXIVE but not PCV20 (pneumococcal 20-valent conjugate vaccine) (CAPVAXIVE-unique serotypes: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, 35B) compared to serotypes covered by PCV20 but not CAPVAXIVE (PCV20-unique serotypes: 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F). Findings were presented at IDWeek 2025 in Atlanta, GA.","length":870,"tagName":"p"},{"type":"text","content":"A total of 15 full-text publications from the U.S., in addition to CDC Active Bacterial Core (ABC) Surveillance reports, were included in the analysis. Of these 15, 13 reported prevalence, five reported incidence, two reported mortality, two reported AMR, one reported health resource utilization (HRU) and PD complications. Results of this systematic literature review showed that CAPVAXIVE-unique serotypes are more prevalent in U.S. adults with PD than PCV20-unique serotypes. Based on two of the publications, PD caused by CAPVAXIVE-unique serotypes have higher rates of resistance to commonly prescribed antibiotics used to treat non-invasive PD. Specific findings fr...